生命科学公司Cytek BioSciences(CTKB)周一盘前股价大涨7.16%,主因其发布的2024年第三季度业绩数据实现显著增长,超出市场预期。
根据公司上周五晚间公布的最新季报,CTKB第三季度实现营收5150万美元,同比增长7.3%;每股收益1美分,而分析师此前的平均预期为每股亏损1美分。这一外延预期的业绩表现显然让投资者对该公司未来发展前景重燃信心。
CTKB表示,营收和利润的增长主要得益于其细胞分析系统产品Aurora和Northern Lights的持续强劲销售。尽管面临通胀和汇率波动等挑战,但公司仍在生产基地扩张等领域取得进展,为下一步发展奠定基础。该公司计划继续深耕细胞分析这一高增长行业,进一步扩大市场份额。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.